1. Home
  2. VGI vs MAIA Comparison

VGI vs MAIA Comparison

Compare VGI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Global Multi-Sector Income Fund of Beneficial Interest

VGI

Virtus Global Multi-Sector Income Fund of Beneficial Interest

SELL

Current Price

$6.47

Market Cap

74.8M

Sector

Finance

ML Signal

SELL

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

SELL

Current Price

$1.10

Market Cap

69.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
VGI
MAIA
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.8M
69.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
VGI
MAIA
Price
$6.47
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
50.5K
★ 439.4K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 12.66%
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.48
$0.89
52 Week High
$8.04
$3.19

Technical Indicators

Market Signals
Indicator
VGI
MAIA
Relative Strength Index (RSI) 28.77 48.45
Support Level N/A N/A
Resistance Level $6.99 $1.49
Average True Range (ATR) 0.10 0.10
MACD -0.03 0.02
Stochastic Oscillator 1.90 30.22

Price Performance

Historical Comparison
VGI
MAIA

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: